Indications and Mechanism of Action
Crizotinib is indicated for patients with ALK‑positive locally advanced or metastatic non‑small cell lung cancer (NSCLC) and patients with ROS1‑positive advanced NSCLC.It selectively inhibits the kinase activity of anaplastic lymphoma kinase (ALK), ROS1 proto‑oncogene (ROS1), and hepatocyte growth factor receptor (c‑Met), blocking signaling pathways that promote tumor cell proliferation and survival.
Latest Price of Genuine Crizotinib
Crizotinib is approved in multiple countries worldwide.The Laos Daewoo version is available as 250 mg × 60 capsules per box, at a price of approximately 157 US dollars per box.
Prices are not fixed and may vary due to region, hospital procurement policies, medical insurance reimbursement, dosage form, and purchasing channel. Patients are advised to consult professional medical personnel for up‑to‑date pricing.
Use in Special Populations
Patients with Hepatic Impairment
Mild hepatic impairment: No dose adjustment required.
Moderate hepatic impairment: Recommended to start with a reduced initial dose.
Severe hepatic impairment: Recommended to use a second‑dose reduction regimen.
Patients with Renal Impairment
Mild to moderate renal impairment: No dose adjustment required.
Severe renal impairment (not requiring dialysis): Recommended to use a second‑dose reduction regimen.
Pediatric and Young Adult Patients
Dosing requires special attention and is usually calculated based on body surface area (BSA).
Recommended dose: 280 mg/m² orally twice daily.The exact dose should be precisely calculated and adjusted according to the detailed table in the prescribing information.
Pregnant Women
Based on its mechanism of action, crizotinib may cause fetal harm.
Females of reproductive potential should use effective contraception during treatment and for 45 days after the last dose.
Breastfeeding Women
Breastfeeding is not recommended during treatment and for 45 days after the last dose.
Male Patients
Due to potential genotoxicity, male patients with female partners of reproductive potential should use condoms during treatment and for 90 days after the last dose.
Fertility
Crizotinib may impair fertility in both females and males.
Geriatric Patients
No overall differences in safety or effectiveness have been observed between patients aged 65 years and older and younger patients.
